Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Cardiovascular

Chris Lieu
August 8, 2018 11:50 PM UTC

Mouse studies suggest inhibiting the integrin CD29 could help treat vascular leakage caused by endotoxemia associated with sepsis. In a lipopolysaccharide (LPS)-induced mouse model of endotoxemia, an anti-CD29 mAb decreased vascular leakage and increased cardiac ejection fraction compared with a control antibody. Also in the model, heterozygous knockout of CD29 decreased vascular leakage compared with normal expression. Next steps could include testing CD29 inhibitors in additional models of endotoxemia...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

University of Helsinki

BCIQ Target Profiles

Integrin beta(1) (CD29)